Compare Altria Group Inc (MO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Sanofi SA — how do they compare? Altria Group Inc trades at $68.15 (market cap $113.36B), while Sanofi SA trades at $42.95 (market cap $103.41B). The key difference: Altria Group Inc and Sanofi SA are close in size by market cap, and Altria Group Inc pays the higher dividend (6.54%). Which is the better fit depends on your goals.
| MO | SNY | |
|---|---|---|
Market Cap | $113.36B | $103.41B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $52.34 |
52-Week Low | $54.72 | $41.33 |
Enterprise Value | $135.57B | $123.44B |
Dividend Yield | 6.54% | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MO trades at $68.18, down 1.02% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing revenue expectations, and maintains a strong 6.4% dividend yield after its 57th consecutive annual increase. Cash flow from operations remains robust at $9.29 billion for 2025, supporting dividend sustainability despite regulatory headwinds.
Outlook is cautiously optimistic with a consensus price target of $68.50, reflecting Wall Street's buy-heavy ratings. Key risks include ongoing FDA litigation, declining cigarette volumes, and high debt levels. The stock offers income appeal but faces secular challenges in the tobacco industry, requiring careful monitoring of regulatory developments and smoke-free segment growth.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
